Reproxalap

Summary

Reproxalap (CHEMBL4297210) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including atopic conjunctivitis and dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 236.7 Da · C12H13ClN2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297210
Name	Reproxalap
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16088030
Molecular formula	C12H13ClN2O
Molecular weight	236.7
InChIKey	GUHFUVLKYSQIOQ-UHFFFAOYSA-N

SMILES: CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O

IUPAC name: 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol

Also known as: ADX-102, ALD-102, NS2, Reproxalap, REPROXALAP

Patent coverage: 323 distinct patent families (664 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 470 (71%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atopic conjunctivitis	3	MONDO:0005642	EFO:0007141
dry eye syndrome	3	MONDO:0006733	EFO:1000906
Sjogren-Larsson syndrome	3	MONDO:0010031	Orphanet:816

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03445650	PHASE3	COMPLETED	RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
NCT06826196	PHASE1/PHASE2	RECRUITING	A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT02406209	PHASE2	COMPLETED	A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
NCT03102034	PHASE1	COMPLETED	Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).